Gene · 170572
HTR3C: 5-hydroxytryptamine receptor 3C
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HTR3C: 5-hydroxytryptamine receptor 3C. Genes, record 170572. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/170572
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q8WXA8 | 5-hydroxytryptamine receptor 3C | 447 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents20
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 35769 | Q8WXA8 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5447 | Q8WXA8 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5053 | Q8WXA8 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2010 | Q8WXA8 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2010 | Q8WXA8 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5053 | Q8WXA8 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5447 | Q8WXA8 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 411 | Q8WXA8 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 411 | Q8WXA8 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 5662 | Q8WXA8 | Espacenet |
1 to 10 of 20
See all 20 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMISULPRIDE | CHEMBL243712 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| CLOTHIAPINE | CHEMBL304902 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| DEXFENFLURAMINE | CHEMBL248702 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DEXFENFLURAMINE HYDROCHLORIDE | CHEMBL1887891 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| FACINICLINE | CHEMBL2151439 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| FACINICLINE HYDROCHLORIDE | CHEMBL5095032 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| MOSAPRIDE | CHEMBL60889 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| PUMOSETRAG | CHEMBL1643880 | Serotonin 3 (5-HT3) receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| RAMOSETRON | CHEMBL1643895 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
| RAMOSETRON HYDROCHLORIDE | CHEMBL3181841 | Serotonin 3 (5-HT3) receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials67
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06887621 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06585540 | AMISULPRIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06581302 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT06166615 | RAMOSETRON | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06040944 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05956600 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05347199 | AMISULPRIDE | PHASE1 | ClinicalTrials.gov | |
| NCT04954365 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT04533724 | AMISULPRIDE | EARLY_PHASE1 | ClinicalTrials.gov |
1 to 10 of 67
See all 67 trialsNIH grants118
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HTR3C papers | Newest fiscal year |
|---|---|---|---|
| K12DA000167 | Clinician Scientist Training Program (CSTP) | 1 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 1 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 1 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 1 | 2025 |
| P30CA124435 | Stanford Cancer Institute | 1 | 2025 |
| R01CA241137 | A microengineered colon cancer-chip designed to investigate tumor-stromal interactions driving cancer progression | 1 | 2025 |
| R01EB023281 | FreeSurfer Development, Maintenance, and Hardening | 1 | 2025 |
| T32CA090314 | Behavioral Oncology Education & Career Development | 1 | 2025 |
| T32HG000044 | Institutional Training Grant in Genome Science | 1 | 2025 |
| U01CA206110 | Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study | 1 | 2025 |
1 to 10 of 118Source NIH's project files
See all 118 nih grantsPapers157
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-Omics and Machine Learning Identify Immune-Linked Gene Signatures for LUAD Stratification. | Genes (Basel) | 2026 | 42792990 | PubTator, text mining | PubMed |
| Integrated Metabolomic and Transcriptomic Analyses Reveal Alterations in the Serotonergic Synapse Pathway and a Robust Diagnostic Model in Ulcerative Colitis. | Metabolites | 2026 | 42042908 | PubTator, text mining | PubMed |
| Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis. | Nat Genet | 2026 | 41917433 | PubTator, text mining | PubMed |
| Neurotransmitter Systems in Alzheimer's Disease. | Curr Issues Mol Biol | 2026 | 41899485 | PubTator, text mining | PubMed |
| Quantifying the fidelity of in vitro human cell culture systems using a biomedical foundation model. | Proc Natl Acad Sci U S A | 2026 | 41860964 | PubTator, text mining | PubMed |
| Transformer-based deep learning enhances discovery in migraine GWAS. | Nat Commun | 2025 | 41372126 | PubTator, text mining | PubMed |
| Impaired Molecular Mechanisms Contributing to Chronic Pain in Patients with Hidradenitis Suppurativa: Exploring Potential Biomarkers and Therapeutic Targets. | Int J Mol Sci | 2025 | 39940809 | PubTator, text mining | PubMed |
| Serotonin Receptors Polymorphisms Are Associated With Cyclic Vomiting Syndrome. | Neurogastroenterol Motil | 2025 | 39888244 | PubTator, text mining | PubMed |
| Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease. | Neurosci Lett | 2024 | 38729598 | PubTator, text mining | PubMed |
| A novel immune-related gene signature for diagnosis and potential immunotherapy of microsatellite stable endometrial carcinoma. | Sci Rep | 2024 | 38355782 | PubTator, text mining | PubMed |
1 to 10 of 157
See all 157 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/170572
GET https://conductscience.org/api/genes/v1/170572/patents